Abstract Library

#4157 Decoding and targeting of metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): MCT1 and MCT4 in the crosshair for precision therapy

Introduction: Mechanisms driving progression from indolent to aggressive and metastatic disease in PanNET are largely unknown. Recent transcriptome and epigenome analyses suggest a stepwise progression model leading to enhanced proliferation, de-differentiation, and metabolic reprogramming. However, the metabolic landscape at different stages and the therapeutic potential of targeting metabolic proteins remain largely uncharacterized.

Conference:

Presenting Author: Sadowski M

Authors: Bräutigam K, Straub J, Bihi A, Andreasi V, Kirchner P,

Keywords: metabolic heterogeneity, 3D model, precision medicine, metabolic subtype, PanNET, hypoxia, lactate efflux, microvessel density, MCT1/MCT4,

#3725 Progression of pancreatic neuroendocrine tumors (PanNETs) to metastatic disease is associated with MCT4 expression and metabolic heterogeneity

Introduction: Up to 50% of patients with PanNETs present with metastasis at time of diagnosis or relapse after surgery, with highly variable dynamics. The mechanisms driving progression from indolent to metastatic disease are largely unknown. Although having great potential for providing novel therapeutic targets, the metabolic landscape at different tumor stages is only poorly understood. Transcriptome and epigenome analyses of PanNET indicate a potential stepwise progression, which is associated with enhanced proliferation, dedifferentiation and hallmarks of hypoxia.

Conference:

Presenting Author: Sadowski M

Authors: Sadowski M, Bräutigam K, Straub J, Andreasi V, Kirchner P,

Keywords: MCT4, metabolic subtypes, aggressive PanNET, patient-derived tumoroid,

#3401 Characterising aggressive pulmonary carcinoids through integrative omics analysis

Introduction: Atypical carcinoids, and our recently identified supra-carcinoids (Alcala et al. 2019) belong to the pulmonary carcinoid (PCA) group of low grade lung neuroendocrine tumors. Little is known about the underlying biology of these tumors, nor why some patients are prone to metastatic disease and tumor recurrence. To date, molecular analysis of these tumors has been limited, particularly with regard to whole-genome sequencing (WGS).

Conference:

Presenting Author:

Authors: Sexton-Oates A, Di Genova A, Alcala N, Mangiante L, Voegele C,

Keywords: pulmonary carcinoid, genome, transcriptome, epigenome, characterisation,

#2992 The PanNENomics Project: A Call for an International Collaborative Effort Built on the Success of the LungNENomics Project

Introduction: Neuroendocrine tumors are rare understudied diseases at the molecular level, especially those occurring in sites outside the lung and the gastrointestinal track. This lack of knowledge has strong implications for the clinical management of these diseases (Rindi et al. Mad Pathol 2018).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Fernandez-Cuesta L

Authors: Fernandez-Cuesta L, Foll M, Walter T, Girard N, Lantuejoul S,

Keywords: Rare Cancers genomics, lungNENomics, panNENomics, supra-carcinoids, tumor maps,